Erythropoietin: Powerful protection of ischemic and post-ischemic brain

Experimental Biology and Medicine

Volumn 239, Issue 11, 2014, Pages 1461-1475

  Nguyen, Anh Q ^a   Cherry, Brandon H ^a   Scott, Gary F ^a   Ryou, Myoung Gwi ^a   Mallet, Robert T ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Apoptosis; blood brain barrier; hypoxia inducible factor; nitric oxide synthase; peroxynitrite; pyruvate

Indexed keywords

APOPTOSIS REPRESSOR WITH CASPASE RECRUITMENT DOMAIN; ERYTHROPOIETIN; GLUTAMIC ACID; HYPOXIA INDUCIBLE FACTOR; MATRIX METALLOPROTEINASE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; PROTEIN BAX; PROTEIN BCL 2; PYRUVIC ACID; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2; NEUROPROTECTIVE AGENT;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CENTRAL NERVOUS SYSTEM FUNCTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR MALFORMATION; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DRUG MECHANISM; ERYTHROPOIESIS; EXCITOTOXICITY; HEART ARREST; HUMAN; HYPOTHERMIA; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INFLAMMATION; MITOCHONDRIAL DYNAMICS; NEUROPROTECTION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXYGEN SUPPLY; REPERFUSION INJURY; SIGNAL TRANSDUCTION; BRAIN; DRUG EFFECTS; UNITED STATES;

BRAIN; BRAIN ISCHEMIA; ERYTHROPOIETIN; HUMANS; NEUROPROTECTIVE AGENTS; UNITED STATES;

EID: 84910096043     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370214523703     Document Type: Article

References (173)

1. Go AS,Mozaffarian D,Roger VL;.Heart disease and stroke statistics – 2013 update.Circulation. 2013;127:e6-245
2. Roger VL,Go AS,Lloyd-Jones DM;.Heart disease and stroke statistics – 2012 update.Circulation. 2012;125:e2-220
3. Xiao F.Bench to bedside: brain edema and cerebral resuscitation: the present and future.Acad Emerg Med. 2002;9:933-46
4. Idris AH,Roberts LJ II,Caruso L,Showstark M,Layon AJ,Becker LB,Vanden Hoek T,Gabrielli A.Oxidant injury occurs rapidly after cardiac arrest, cardiopulmonary resuscitation, and reperfusion.Crit Care Med. 2005;33:2043-8
5. Nadkarni VM,Larkin GL,Peberdy MA,Carey SM,Kaye W,Mancini ME,Nichol G,Lane-Truitt T,Potts J,Ornato JP,Berg RA;.First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults.JAMA. 2006;295:50-7
6. Nolan JP,Laver SR,Welch CA,Harrison DA,Gupta V,Rowan K.Outcome following admission to UK intensive care units after cardiac arrest: a secondary analysis of the ICNARC Case Mix Programme Database.Anesthesia. 2007;62:1207-16
7. Madl C,Holzer M.Brain function after resuscitation from cardiac arrest.Curr Opin Crit Care. 2004;10:213-7
8. Westfal RE,Reissman S,Doering G.Out-of-hospital cardiac arrests: an 8-year New York City experience.Am J Emerg Med. 1996;14:364-8
9. Böttiger BW,Grabner C,Bauer H,Bode C,Weber T,Motsch J,Martin E.Long term outcome after out-of-hospital cardiac arrest with physician staffed emergency medical services: the Utstein style applied to a midsized urban/suburban area.Heart. 1999;82:674-9
10. Neumar RW,Nolan JP,Adrie C,Aibiki M,Berg RA,Böttiger BW,Callaway C,Clark RSB,Geocadin RG,Jauch EC,Kern KB,Laurent I,Longstreth WT,Merchant RM,Morley P,Morrison LJ,Nadkarni V,Peberdy MA,Rivers EP,Rodriguez-Nunez A,Sellke FW,Spaulding C,Sunde K,Vanden Hoek T.Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication.Circulation. 2008;118:2452-83
11. White BC,Sullivan JM,DeGracia DJ,O’Neil BJ,Neumar RW,Grossman LI,Rafols JA,Krause GS.Brain ischemia and reperfusion: molecular mechanisms of neuronal injury.J Neurol Sci. 2000;179:1-33
12. Guyot LL,Diaz FG,O-Regan MH,Song D,Phillis JW.The effect of streptozotocin-induced diabetes on the release of excitotoxic and other amino acids from the ischemic rat cerebral cortex.Neurosurgery. 2011;48:385-90
13. Belousov AB.Novel model for the mechanisms of glutamate-dependent excitotoxicity: role of neuronal gap junctions.Neurosci Lett. 2012;524:16-9
14. Konstady BB.The role of glutamate in neuronal ischemic injury: the role of spark in fire.Neurol Sci. 2012;33:223-37
15. Swanson RA,Ying W,Kauppinen TM.Astrocyte influences on ischemic neuronal death.Curr Molec Med. 2004;4:193-205
16. Mayhan WG,Didion SP.Glutamate-induced disruption of the blood-brain barrier in rats.Role of nitric oxide. Stroke. 1996;27:965-9
17. Nicotera P,Lipton SA.Excitotoxins in neuronal apoptosis and necrosis.J Cereb Blood Flow Metab. 1999;19:583-91
18. Manukhina EB,Downey HF,Mallet RT.Role of nitric oxide in cardiovascular adaptation to intermittent hypoxia.Exp Biol Med. 2006;231:343-65
19. Basu S,Liu X,Nozari A,Rubertsson S,Miclescu A,Wiklund L.Evidence for time-dependent maximum increase of free radical damage and eicosanoid formation in the brain as related to duration of cardiac arrest and cardio-pulmonary resuscitation.Free Radic Res. 2003;37:251-6
20. Chao CC,Hu S,Molitor TW,Shaskan EG,Peterson PK.Activated microglia mediate neuronal cell injury via a nitric oxide mechanism.J Immunol. 1992;149:2736-41
21. Boje KM,Arora PK.Microglial-produced nitric oxide and reactive nitrogen oxides mediate neuronal cell death.Brain Res. 1992;587:250-6
22. Guix FX,Uribesalgo I,Coma M,Muñoz FJ.The physiology and pathophysiology of nitric oxide in the brain.Progr Neurobiol. 2005;76:126-52
23. Brock MV,Blue ME,Lowenstein CJ,Northington FA,Lange MS,Johnston MV,Baumgartner WA.Induction of neuronal nitric oxide after hypothermic circulatory arrest.Ann Thorac Surg. 1996;62:1313-20
24. Chuang Y-C,Chen S-D,Liou C-W,Lin T-K,Chang W-N,Chan SHH,Chang AYW.Contribution of nitric oxide, superoxide anion, and peroxynitrite to activation of mitochondrial apoptotic signaling in hippocampal CA3 subfield following experimental temporal lobe status epilepticus.Epilepsia. 2009;50:731-46
25. Neria F,del Carmen Serrano-Perez M,Velasco P,Urso K,Tranque P,Cano E.NFATc3 promotes Ca2+-dependent MMP3 expression in astroglial cells.Glia. 2013;61:1052-66
26. Ralay Ranaivo H,Hodge JN,Choi N,Wainwright MS.Albumin induces upregulation of matrix metalloproteinase-9 in astrocytes via MAPK and reactive oxygen species-dependent pathways.J Neuroinflammation. 2012;9:68-68
27. Hsieh HL,Chi PL,Lin CC,Yang CC,Yang CM.Up-regulation of ROS-dependent matrix metalloproteinase-9 from high-glucose-challenged astrocytes contributes to the neuronal apoptosis.Mol Neurobiol. 2014;:
28. Gottschall PE,Deb S.Regulation of matrix metalloproteinase expressions in astrocytes, microglia and neurons.Neuroimmunomodulation. 1996;3:69-75
29. Harkness KA,Adamson P,Sussman JD,Davies-Jones GA,Greenwood J,Woodroofe MN.Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium.Brain. 2000;123:698-709
30. Lee JM,Yin KJ,Hsin I,Chen S,Fryer JD,Holtzman DM,Hsu CY,Xu J.Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy.Ann Neurol. 2003;54:379-82
31. Wang L,Zhang ZG,Zhang RL,Gregg SR,Hozeska-Solgot A,LeTourneau Y,Wang Y,Chopp M.Matrix metalloproteinase 2 (MMP2) and MMP9 secreted by erythropoietin-activated endothelial cells promote neural progenitor cell migration.J Neurosci. 2006;26:5996-6003
32. Gidday JM,Gasche YG,Copin JC,Shah AR,Perez RS,Shapiro SD,Chan PH,Park TS.Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia.Am J Physiol Heart Circ Physiol. 2005;289:H558-68
33. Lischper M,Beuck S,Thanabalasundaram G,Pieper C,Galla HJ.Metalloproteinase mediated occluding cleavage in the cerebral microcapillary endothelium under pathological conditions.Brain Res. 2010;1326:114-27
34. Lehner C,Gehwolf R,Tempfer H,Krizbai I,Hennig B,Bauer HC,Bauer H.Oxidative stress and blood-brain barrier dysfunction under particular consideration of matrix metalloproteinases.Antioxid Redox Signal. 2011;15:1305-23
35. Abdul Muneer PM,Alikunju S,Szlachetka AM,Haorah J.The mechanism of cerebral vascular dysfunction and neuroinflammation by MMP-mediated degradation of VEGFR-2 in alcohol ingestion.Arterioscler Thromb Vasc Biol. 2012;32:1167-77
36. Okamoto T,Akuta T,Tamura F,van der Vliet A,Akaike T.Molecular mechanism for activation and regulation of matrix metalloproteinases during bacterial infections and respiratory inflammation.Biol Chem. 2004;385:997-1006
37. Gasche Y,Soccal PM,Kanemitsu M,Copin JC.Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain.Front Biosci. 2006;11:1289-1301
38. Planas AM,Solé S,Justicia C.Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia.Neurobiol Dis. 2001;8:834-46
39. Broughton BR,Reutens DC,Sobey CG.Apoptotic mechanisms after cerebral ischemia.Stroke. 2009;40:e331-9
40. Sims NR,Muyderman H.Mitochondria, oxidative metabolism and cell death in stroke.Biochim Biophys Acta. 2010;1802:80-92
41. Belayev L,Zhao WZ,Busto R,Ginsberg MD.Transient middle cerebral artery occlusion by intraluminal suture. 1. Three-dimensional autoradiographic analysis of local cerebral glucose metabolism-blood flow interrelationships during ischemia and early recirculation.J Cereb Blood Flow Metab. 1997;17:1266-80
42. Ferrer I,Planas AM.Signaling of cell death and cell survival following cerebral ischemia: life and death struggle in the penumbra.J Neuropathol Exp Neurol. 2003;62:329-39
43. Jordan J,de Groot PW,Galindo MF.Mitochondria: the headquarters in ischemis-induced neuronal death.Cent Nerv Syst Agents Med Chem. 2011;11:98-106
44. Bredesen DE,Mehlen P,Rabizadeh S.Apoptosis and dependence receptors: a molecular basis for cellular addiction.Physiol Rev. 2004;84:411-30
45. Yeh CH,Wang YC,Wu YC,Lin YM,Lin PJ.Ischemic preconditioning or heat shock pretreatment ameliorates neuronal apoptosis following hypothermic circulatory arrest.J Thorac Cardiovasc Surg. 2004;128:203-10
46. Böttiger BW,Schmitz B,Wiessner C,Vogel P,Hossman K-A.Neuronal stress response and neuronal cell damage after cardiocirculatory arrest in rats.J Cereb Blood Flow Metab. 1998;18:1077-87
47. Teschendorf P,Padosch SA,Spöhr F,Albertsmeier M,Schneider A,Vogel P,Choi Y-H,Böttiger BW,Popp E.Time course of caspase activation in selectively vulnerable brain areas following global cerebral ischemia due to cardiac arrest in rats.Neurosci Lett. 2008;448:194-9
48. Tamatani M,Ogawa S,Nunez G,Tohyama M.Growth factors prevent changes in Bcl-2 and Bax expression and neuronal apoptosis induced by nitric oxide.Cell Death Differ. 1998;5:911-9
49. Tamatani M,Ogawa S,Niitsu Y,Tohyama M.Involvement of Bcl-2 family and caspase-3-like protease in NO-mediated neuronal apoptosis.J Neurochem. 1998;71:1588-96
50. Fisher JW.Landmark advances in the development of erythropoietin.Exp Biol Med. 2010;235:1398-1411
51. Semenza GL.Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis.Hematol Oncol Clin North Am. 1994;8:863-84
52. Ishii Y,Sawada T,Murakami T,Sakuraoka Y,Shiraki T,Shimizu A,Kubota K,Fuchinoue S,Teraoka S.Renoprotective effect of erythropoietin against ischaemia-reperfusion injury in a non-human primate model.Nephrol Dial Transplant. 2011;26:1157-62
53. Moore E,Bellomo R.Erythropoietin (EPO) in acute kidney injury.Ann Intensive Care. 2011;1:3-3
54. Benderro GF,LaManna JC.Kidney EPO expression during chronic hypoxia in aged mice.Adv Exp Med Biol. 2013;765:9-14
55. Fisher JW.Erythropoietin: physiology and pharmacology update.Exp Biol Med. 2003;228:1-14
56. Chong ZZ,Kang J-Q,Maiese K.Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways.Brit J Pharmacol. 2003;138:1107-18
57. Maiese K,Li F,Chong ZZ.New avenues of exploration for erythropoietin.JAMA. 2005;293:90-5
58. Hasselblatt M,Ehrenreich H,Sirén A-L.The brain erythropoietin system and its potential for therapeutic exploitation in brain disease.J Neurosurg Anesthesiol. 2006;18:132-8
59. McPherson RJ,Juul SE.Recent trends in erythropoietin-mediated neuroprotection.Int J Devel Neurosci. 2008;26:103-11
60. Rabie T,Marti HH.Brain protection by erythropoietin: a manifold task.Physiology. 2008;23:263-74
61. Mammis A,McIntosh TK,Maniker AH.Erythropoietin as a neuroprotective agent in traumatic brain injury.Surg Neurol. 2009;71:527-31
62. Sadamoto Y,Igase K,Sakanaka M,Sato K,Otsuka H,Sasaki S,Masuda S,Sasaki R.Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery.Biochem Biophys Res Commun. 1998;253:26-32
63. Sirén A,Fratelli M,Brines M,Goemans C,Casagrande S,Lewczuk P,Keenan S,Gleiter C,Pasquali C,Capobianco A,Mennini T,Heumann R,Cerami A,Ehrenreich H,Ghezzi P.Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress.Proc Natl Acad Sci USA. 2001;98:4044-9
64. Kumral A,Tugyan K,Gonenc S,Genc K,Genc S,Sonmez U,Yilmaz O,Duman N,Uysal N,Ozkan H.Protective effects of erythropoietin against ethanol-induced apoptotic neurodegeneration and oxidative stress in the developing C57BL/6 mouse brain.Devel Brain Res. 2005;160:146-56
65. Calapai G,Marciano MC,Corica F,Allegra A,Parisi A,Frisina N,Caputi AP,Buemi M.Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation.Eur J Pharmacol. 2000;401:349-56
66. Kilic E,Kilic Ü,Soliz J,Bassetti CL,Gassmann M,Hermann DM.Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways.FASEB J. 2005;19:2026-8
67. Brines ML,Ghezzi P,Keenan S,Agnello D,de Lanerolle NC,Cerami C,Itri LM,Cerami A.Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.Proc Natl Acad Sci USA. 2000;97:10526-31
68. Xiong Y,Mahmood A,Meng Y,Zhang Y,Qu C,Schallert T,Chopp M.Delayed administration of erythropoietin reducing hippocampal cell loss, enhancing angiogenesis and neurogenesis, and improving functional outcome following traumatic brain injury in rats: comparison of treatment with single and triple dose.J Neurosurg. 2010;113:598-608
69. Popp E,Vogel P,Teschendorf P,Böttiger BW.Effects of the application of erythropoietin on cerebral recovery after cardiac arrest in rats.Resuscitation. 2007;74:344-51
70. Witthuhn BA,Quelle FW,Silvennoinen O,Yi T,Tang B,Miura O,Ihle JN.JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.Cell. 1993;74:227-36
71. Crow MT,Mani K,Nam Y-J,Kitsis RN.The mitochondrial death pathway and cardiac myocyte apoptosis.Circ Res. 2004;95:957-70
72. Baines CP.The cardiac mitochondrion: nexus of stress.Annu Rev Physiol. 2010;72:61-80
73. Vairano M,Russo CD,Pozzoli G,Battaglia A,Scambia G,Tringali G,Aloe-Spiriti MA,Preziosi P,Navara P.Erythropoietin exerts anti-apoptotic effects on rat microglial cells in vitro.Eur J Neurosci. 2002;16:584-92
74. Wen TC,Sadamoto Y,Tanaka J,Zhu PX,Nakata K,Ma YJ,Hata R,Sakanaka M.Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up-regulating Bcl-xL expression.J Neurosci Res. 2002;67:795-803
75. Noguchi CT,Asavaritikrai P,Teng R,Jia Y.Role of erythropoietin in the brain.Crit Rev Oncol Hematol. 2007;64:159-71
76. Digicaylioglu M,Lipton SA.Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaP signaling cascades.Nature. 2001;412:641-7
77. Genc S,Koroglu TF,Genc K.Erythropoietin as a novel neuroprotectant.Restor Neurol Neurosci. 2004;22:105-19
78. Deveraux QL,Roy N,Stennicke HR,Van Arsdale T,Zhou Q,Srinivasula SM,Alnemri ES,Salvesen GS,Reed JC.IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases.EMBO J. 1998;17:2215-23
79. Shiozaki EN,Chai J,Rigotti DJ,Riedl SJ,Li P,Srinivasula SM,Alnemri ES,Fairman R,Shi Y.Mechanism of XIAP-mediated inhibition of caspase-9.Mol Cell. 2003;11:519-27
80. Zhang J,Zhu Y,Zhou D,Wang Z,Chen G.Recombinant human erythropoietin (rhEPO) alleviates early brain injury following subarachnoid hemorrhage in rats: possible involvement of Nrf2-ARE pathway.Cytokine. 2010;52:252-7
81. Sifringer M,Brait D,Weichelt U,Zimmerman G,Endesfelder S,Brehmer F,von Haefen C,Friedman A,Soreq H,Bendix I,Gerstner B,Felderhoff-Mueser U.Erythropoietin attenuates hyperoxia-induced oxidative stress in the developing rat brain.Brain Behav Immun. 2010;24:792-9
82. Innamorato NG,Rojo AI,Garcia-Yagüe AJ,Yamamoto M,de Ceballos ML,Cuadrado A.The transcription factor Nrf2 is a therapeutic target against brain inflammation.J Immunol. 2008;181:680-9
83. Zhang GL,Wang W,Kang YX,Xue Y,Yang H,Zhou CM,Shi GM.Chronic testosterone propionate supplement activated the Nrf2-ARE pathway in the brain and ameliorated the behaviors of age rats.Behav Brain Res. 2013;252:388-95
84. Genc K,Egrilmez MY,Genc S.Erythropoietin induces nuclear translocation of Nrf2 and heme oxygenase-1 expression in SH-SY5Y cells.Cell Biochem Funct. 2010;28:197-201
85. Jin R,Song Z,Yu S,Piazza A,Nanda A,Penninger JM,Granger DN,Li G.Phosphatidylinositol-3-kinase gamma plays a central role in blood-brain barrier dysfunction in acute experimental stroke.Stroke. 2011;42:2033-44
86. McMahon M,Itoh K,Yamamoto M,Hayes JD.Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression.J Biol Chem. 2003;278:21592-600
87. Villeneuve NF,Lau A,Zhang DD.Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases.Antioxid Redox Signal. 2010;13:1699-1712
88. Uruno A,Motohashi H.The Keap1-Nrf2 system as an in vivo sensor for electrophiles.Nitric Oxide. 2011;25:153-60
89. Genc S,Egrilmez MY,Genc K.Endothelial nitric oxide-mediated Nrf2 activation as a novel mechanism for vascular and neuroprotection by erythropoietin in experimental subarachnoid hemorrhage.Med Hypotheses. 2006;67:424-424
90. Buckley BJ,Li S,Whorton AR.Keap1 modification and nuclear accumulation in response to S-nitrosocysteine.Free Radic Biol Med. 2008;44:692-8
91. Li Y,Ogle ME,Wallace GC,Lu ZY,Yu SP,Wei L.Erythropoietin attenuates intracerebral hemorrhage by diminishing matrix metalloproteinases and maintaining blood-brain barrier integrity in mice.Acta Neurochir. 2008;105:105-12
92. Kadri Z,Petitfrère E,Boudot C,Freyssinier J-M,Fichelson S,Mayeux P,Emonard H,Hornebeck W,Haye B,Billat C.Erythropoietin induction of tissue inhibitors of metalloproteinase-1 expression and secretion is mediated by mitogen-activated protein kinase and phsphatidylinositol 3-kinase pathways.Cell Growth Differen. 2000;11: 573-80
93. Villa P,Bigini P,Mennini T,Agnello D,Laragione T,Cagnotto A,Viviani B,Marinovich M,Cerami A,Coleman TR,Brines M,Ghezzi P.Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis.J Exp Med. 2003;198:971-75
94. Kawakami M,Sekiguchi M,Sato K,Kozaki S,Takahashi M.Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia.J Biol Chem. 2001;276:39469-75
95. Won YJ,Yoo JY,Lee JH,Hwang SJ,Kim D,Hong HN.Erythropoietin is neuroprotective on GABAergic neurons against kainic acid-excitotoxicity in the rat spinal cell cultures.Brain Res. 2007;1154:31-9
96. Kamal A,Al Shaibani T,Ramakers G.Erythropoietin decreases the excitatory neurotransmitter release probability and enhances synaptic plasticity in mice hippocampal slices.Brain Res. 2011;1410:33-7
97. Pytte M,Steen PA.Are we closer to a new strategy in the treatment of cardiac arrest?.Resuscitation. 2009;80:613-4
98. Ehrenreich H,Hasselblatt M,Dembowski C,Cepek L,Lewczuk P,Stiefel M,Rustenbeck H-H,Breiter N,Jacob S,Knerlich F,Bohn M,Poser W,Rüther E,Kochen M,Gefeller O,Gleiter C,Wessel TC,De Ryck M,Itri L,Prange H,Cerami A,Brines M,Sirén A-L.Erythropoietin therapy for acute stroke is both safe and beneficial.Molec Med. 2002;8:495-505
99. Cariou A,Claessens Y-E,Pène F,Marx J-S,Spaulding C,Hababou C,Casadevall N,Mira J-P,Carli P,Hermine O.Early high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: a matched control study.Resuscitation. 2008;76:397-404
100. Grmec Š,Strnad M,Kupnik D,Sinkovič A,Gazmuri RJ.Erythropoietin facilitates the return of spontaneous circulation and survival in victims of out-of-hospital cardiac arrest.Resuscitation. 2009;80:631-7
101. Ehrenreich H,Weissenborn K,Prange H,Schneider D,Weimar C,Wartenberg K,Schellinger PD,Bohn M,Becker H,Wegrzyn M,Jähnig P,Herrmann M,Knauth M,Bähr M,Heide W,Wagner A,Schwab S,Reichmann H,Schwendemann G,Dengler R,Kastrup A,Bartels C,EPO Stroke Trial Group.Recombinant human erythropoietin in the treatment of acute ischemic stroke.Stroke. 2009;40:e647-56
102. Green AR.Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly.Br J Pharmacol. 2008;153:S325-38
103. Hacke W,Kaste M,Bluhmki E,Brozman M,Davalos A,Guidetti D,Larrue V,Lees KR,Medeghri Z,Machnig T,Schneider D,von Kummer R,Wahlgren N,Toni D.Thrombolysis with alteplase 3 to 4.5 h after acute ischemic stroke.N Engl J Med. 2008;359:1317-29
104. Jia L,Chopp M,Zhang L,Lu M,Zhang Z.Erythropoietin in combination of tissue plasminogen activator exacerbates brain hemorrhage when treatment is initiated 6 hours after stroke.Stroke. 2010;41:2071-6
105. Banks WA,Jumbe NL,Farrell CL,Niehoff ML,Heatherington AC.Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoietin alfa.Eur J Pharmacol. 2004;505:93-101
106. Juul SE,McPherson RJ,Farrell FX,Jolliffe L,Ness DJ,Gleason CA.Erythropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin.Biol Neonate. 2004;85:138-44
107. Dame C,Juul SE,Christensen RD.The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential.Biol Neonate. 2001;79:228-35
108. Haiden N,Klebermass K,Cardona F,Schwindt J,Berger A,Kohlhauser-Vollmuth C,Jilma B,Pollak A.A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity.Pediatrics. 2006;118:180-8
109. Marti HH,Gassmann M,Wenger RH,Kvietikova I,Morganti-Kossmann MC,Kossmann T,Trentz O,Bauer C.Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain.Kidney Int. 1997;51:416-8
110. Buemi M,Allegra A,Corica F,Floccari F,D’Avella D,Aloisi C,Calapai G,Iacopino G,Frisina N.Intravenous recombinant erythropoietin does not lead to an increase in cerebrospinal fluid erythropoietin concentration.Nephrol Dial Transplant. 2000;15:422-3
111. McPherson RJ,Juul SE.Recent trends in erythropoietin-mediated neuroprotection.Int J Devel Neurosci. 2008;26:103-11
112. García-Yébenes I,Sobrado M,Zarruk JG,Castellanos M,Pérez de la Ossa N,Dávalos A,Serena J,Lizasoain I,Moro MA.A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke.Stroke. 2011;42:196-203
113. Baciu I,Oprisiu C,Deverenco P,Vasile V,Muresan A,Hriscu M,Chris I.The brain and other sites of erythropoietin production.Rom J Physiol. 2000;37:3-14
114. Marti HH.Erythropoietin and the hypoxic brain.J Exp Biol. 2004;207:3233-42
115. Benderro GF,Sun X,Kuang Y,LaManna JC.Decreased VEGF expression and microvascular density, but increased HIF-1 and 2α accumulation and EPO expression in chronic moderate hyperoxia in the mouse brain.Brain Res. 2012;1471:46-55
116. Dame C,Bartmann P,Wolber E-M,Fahnenstich H,Hofmann D,Fandrey J.Erythropoietin gene expression in different areas of the developing human central nervous system.Dev Brain Res. 2000;125:69-74
117. Juul SE,Anderson DK,Li Y,Christensen RD.Erythropoietin and erythropoietin receptor in the developing human central nervous system.Pediatr Res. 1998;43:40-4
118. Nagai A,Nakagawa E,Choi HB,Hatori K,Kobayashi S,Kim SU.Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture.J Neuropathol Exp Neurol. 2001;60:386-92
119. Sakanaka M,Wen TC,Matsuda S,Masuda S,Morishita E,Nagao M,Sasaki R.In vivo evidence that erythropoietin protects neurons from ischemic damage.Proc Natl Acad Sci USA. 1998;95:4635-40
120. Nangaku M,Eckardt KU.Hypoxia and the HIF system in kidney disease.J Mol Med (Berl). 2007;85:1325-30
121. Haase VH.Regulation of erythropoiesis by hypoxia-inducible factors.Blood Rev. 2013;27:41-53
122. Fandrey J.Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression.Am J Physiol Regul Integr Comp Physiol. 2004;286:R977-88
123. Semenza GL.Expression of hypoxia-inducible factor 1: mechanisms and consequences.Biochem Pharmacol. 2000;59:47-53
124. Jelkmann W.Regulation of erythropoietin production.J Physiol. 2011;589:1251-8
125. Bernaudin M,Bellail A,Marti HH,Yvon A,Vivien D,Duchatelle I,Mackenzie ET,Petit E.Neurons and astrocytes express EPO mRNA: oxygen-sensing mechanisms that involve the redox-state of the brain.Glia. 2000;30:271-8
126. Lee J-Y,Kim Y-H,Koh J-Y.Protection by pyruvate against transient forebrain ischemia in rats.J Neurosci. 2001;21:RC171(1-6)
127. Mongan PD,Capacchione J,Fontana JL,West S,Bünger R.Pyruvate improves cerebral metabolism during hemorrhagic shock.Am J Physiol Heart Circ Physiol. 2001;281:H854-64
128. Kim T-Y,Yi J-S,Chung S-J,Kim D-K,Byun H-R,Lee J-Y,Koh J-Y.Pyruvate protects against kainite-induced epileptic brain damage in rats.Exp Neurol. 2007;208:159-67
129. Sharma P,Karian J,Sharma S,Liu S,Mongan PD.Pyruvate ameliorates post ischemic injury of rat astrocytes and protects them against PARP mediated cell death.Brain Res. 2003;992:104-13
130. Sharma AB,Barlow MA,Yang SH,Simpkins JW,Mallet RT.Pyruvate enhances neurological recovery following cardiopulmonary arrest and resuscitation.Resuscitation. 2008;76:108-19
131. Sharma AB,Knott EM,Bi J,Martinez RR,Sun J,Mallet RT.Pyruvate improves cardiac electromechanical and metabolic recovery from cardiopulmonary arrest and resuscitation.Resuscitation. 2005;66:71-81
132. Fukushima M,Lee SM,Moro N,Hovda DA,Sutton RL.Metabolic and histologic effects of sodium pyruvate treatment in the rat after cortical contusion injury.J Neurotrauma. 2009;26:1095-110
133. Ryou MG,Liu R,Ren M,Sun J,Mallet RT,Yang SH.Pyruvate protects the brain against ischemia-reperfusion injury by activating the erythropoietin signaling pathway.Stroke. 2012;43:1101-7
134. Miller LP,Oldendorf WH.Regional kinetic constants for blood-brain barrier pyruvic acid transport in conscious rats by the monocarboxylic acid carrier.J Neurochem. 1986;46:1412-6
135. Steele RD.Blood-brain barrier transport of the alpha-keto acid analogs of amino acids.Fed Proc. 1986;45:2060-4
136. Lin T,Koustova E,Chen H,Rhee PM,Kirkpatrick J,Alam HB.Energy substrate-supplemented resuscitation affects brain monocarboxylate transporter levels and gliosis in a rat model of hemorrhagic shock.J Trauma. 2005;59:1191-1202
137. Wang Y,Guo SZ,Bonen A,Li RC,Kheirandish-Gozal L,Zhang SX,Brittian KR,Gozal D.Monocarboxylate transporter 2 and stroke severity in a rodent model of sleep apnea.J Neurosci. 2011;31:10241-8
138. Mallet RT.Pyruvate: metabolic protector of cardiac performance.Proc Soc Exp Biol Med. 2000;223:136-48
139. Mallet RT,Sun J,Knott EM,Sharma AB,Olivencia-Yurvati AH.Metabolic cardioprotection by pyruvate: recent progress.Exp Biol Med. 2005;230:435-43
140. Mallet RT,Sun J.Antioxidant properties of myocardial fuels.Mol Cell Biochem. 2003;253:103-11
141. Constantopoulos G,Barranger JA.Nonenzymatic decarboxylation of pyruvate.Anal Biochem. 1984;139:353-8
142. DeBoer LW,Bekx PA,Han L,Steinke L.Pyruvate enhances recovery of rat hearts after ischemia and reperfusion by preventing free radical generation.Am J Physiol Heart Circ Physiol. 1993;265:H1571-6
143. Vásquez-Vivar J,Denicola A,Radi R,Augusto O.Peroxynitrite-mediated decarboxylation of pyruvate to both carbon dioxide and carbon dioxide radical anion.Chem Res Toxicol. 1997;10:786-94
144. Bassenge E,Sommer O,Schwemmer M,Bünger R.Antioxidant pyruvate inhibits cardiac formation of reactive oxygen species through changes in redox state.Am J Physiol Heart Circ Physiol. 2000;279:H2431-8
145. Tejero-Taldo MI,Caffrey JL,Sun J,Mallet RT.Antioxidant properties of pyruvate mediate its potentiation of β-adrenergic inotropism in stunned myocardium.J Mol Cell Cardiol. 1999;31:1863-72
146. Hagar H,Ueda N,Shah S.Role of reactive oxygen metabolites in DNA damage and cell death in chemical hypoxic injury to LLC-PK1 cells.Am J Physiol Renal Fluid Electrolyte Physiol. 1996;271:F209-15
147. Ramakrishnan N,Chen R,McClain DE,Bünger R.Pyruvate prevents hydrogen peroxide-induced apoptosis.Free Radic Res. 1998;29:283-95
148. Sileri P,Schena S,Morini S,Rastellini C,Pham S,Benedetti E,Cicalese L.Pyruvate inhibits hepatic ischemia-reperfusion injury in rats.Transplantation. 2001;72:27-30
149. Lee YJ,Kang IJ,Bünger R,Kang YH.Mechanisms of pyruvate inhibition of oxidant-induced apoptosis in human endotelial cells.Microvasc Res. 2003;66:91-101
150. Lee YJ,Kang IJ,Bünger R,Kang YH.Enhanced survival effect of pyruvate correlates MAPK and NF-κB activation in hydrogen peroxide-treated human endothelial cells.J Appl Physiol. 2004;96:793-801
151. Wang XF,Cynader MS.Pyruvate released by astrocytes protects neurons from copper-catalyzed cysteine neurotoxicity.J Neurosci. 2001;21:3322-31
152. Alvarez G,Ramos M,Ruiz F,Satrústegui J,Bogónez E.Pyruvate protection against β-amyloid-induced neuronal death: role of mitochondrial redox state.J Neurosci Res. 2003;73:260-9
153. Mazzio EA,Soliman KF.Cytoprotection of pyruvic acid and reduced beta-nicotinamide adenine dinucleotide against hydrogen peroxide toxicity in neuroblastoma cells.Neurochem Res. 2003;28:733-41
154. Wang X,Perez E,Liu R,Yan L-J,Mallet RT,Yang S-H.Pyruvate protects mitochondria from oxidative stress in human neuroblastoma SK-N-SH cells.Brain Res. 2007;1132:1-9
155. Levy JH,Tanaka KA.Inflammatory response to cardiopulmonary bypass.Ann Thorac Surg. 2003;75:715-20
156. Van Harten AE,Scheeren TW,Absalom AR.A review of postoperative cognitive dysfunction and neuroinflammation associated with cardiac surgery and anaesthesia.Anaesthesia. 2012;67:280-93
157. Ryou MG,Flaherty DC,Hoxha B,Gurji H,Sun J,Hodge LM,Olivencia-Yurvati AH,Mallet RT.Pyruvate-enriched cardioplegia suppresses cardiopulmonary bypass-induced myocardial inflammation.Ann Thorac Surg. 2010;90:1529-35
158. Sharma P,Mongan PD.Hypertonic sodium pyruvate solution is more effective than Ringers ethyl pyruvate in the treatment of hemorrhagic shock.Shock. 2010;33:532-40
159. Lu H,Forbes RA,Verma A.Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis.J Biol Chem. 2002;277:23111-5
160. Dalgard CL,Lu H,Mohyeldin A,Verma A.Endogenous 2-oxoacids differentially regulate expression of oxygen sensors.Biochem J. 2004;380:419-24
161. Lu H,Dalgard CL,Mohyeldin A,McFate T,Tait AS,Verma A.Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1.J Biol Chem. 2005;280:41928-39
162. Ryou MG,Flaherty DC,Hoxha B,Sun J,Gurji H,Rodriguez S,Bell G,Olivencia-Yurvati AH,Mallet RT.Pyruvate-fortified cardioplegia evokes myocardial erythropoietin signaling in swine undergoing cardiopulmonary bypass.Am J Physiol Heart Circ Physiol. 2009;297:H1914-22
163. Ryou MG,Choudhury GR,Winters A,Xie L,Mallet RT,Yang SH.Pyruvate minimizes rtPA toxicity from in vitro oxygen glucose deprivation.Brain Res. 2013;1530:66-75
164. Gurji HA,White DW,Hoxha B,Sun J,Harbor JP,Schulz DR,Williams AG,Olivencia-Yurvati AH,Mallet RT.Pyruvate-enriched resuscitation: metabolic support of post-ischemic hindlimb muscle in hypovolemic goats.Exp Biol Med. 2014;:
165. Hermann HP,Pieske B,Schwarzmüller E,Keul J,Just H,Hasenfuss G.Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study.Lancet. 1999;353:1321-3
166. Hermann HP,Arp J,Pieske B,Kögler H,Baron S,Janssen PM,Hasenfuss G.Improved systolic and diastolic myocardial function with intracoronary pyruvate in patients with congestive heart failure.Eur J Heart Fail. 2004;6:213-8
167. Schillinger W,Hünlich M,Sossalia S,Hermann HP,Hasenfuss G.Intracoronary pyruvate in cardiogenic shock as an adjunctive therapy to catecholamines and intra-aortic balloon pump shows beneficial effects on hemodynamics.Clin Res Cardiol. 2011;100:433-8
168. Olivencia-Yurvati AH,Blair JL,Baig M,Mallet RT.Pyruvate-enhanced cardioprotection during surgery with cardiopulmonary bypass.J Cardiothorac Vasc Anesth. 2003;17:715-20
169. Fink MP.Ringer’s ethyl pyruvate solution: a novel resuscitation fluid.Minerva Anesthesiol. 2001;67:190-2
170. Fink MP.Ethyl pyruvate: a novel anti-inflammatory agent.J Intern Med. 2007;261:349-62
171. Venkataraman R,Kellum JA,Song M,Fink MP.Resuscitation with Ringer’s ethyl pyruvate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate concentrations in a rat model of lipopolysaccharide-induced shock.Shock. 2002;18:507-12
172. Yang R,Gallo DJ,Baust JJ,Uchiyama T,Watkins SK,Delude RL,Fink MP.Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock.Am J Physiol Gastrointest Liver Physiol. 2002;283:G212-21
173. Mulier KE,Beilman GJ,Conroy MJ,Taylor JH,Skarda DE,Hammer BE.Ringer’s ethyl pyruvate in hemorrhagic shock and resuscitation does not improve early hemodynamics or tissue energetics.Shock. 2005;23:248-52